Ritlecitinib price

Ritlecitinib (Ritlecitinib) is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older. It is generally not recommended to be used in combination with otherJAK inhibitors, biological immunomodulators, cyclosporine or other potent immunosuppressants. ALLEGRO-LT is an ongoing Phase 3, open-label, long-term study investigating the safety and efficacy of LITFULO in adults with alopecia areata who have lost 25% or more of their hair, and in adolescents with alopecia areata who have lost 50% or more of their hair.

Ritexitinib is an inhibitor ofJAK3 and TEC family kinases. Inhibition ofJAK3 and TEC kinase family members may block the signaling of cytokines and the cytolytic activity of T cells, which is related to the pathogenesis of alopecia areata. Regulatory applications for ritixitinib to treat alopecia areata have been submitted for review in countries around the world, including China, the European Union, Japan and the United Kingdom, and ritixitinib is also being evaluated in vitiligo, Crohn's disease and ulcerative colitis.

The most common AEs occurring in at least 1% of patients over 24 weeks include headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, increased serum creatinine phosphokinase, herpes zoster, decreased red blood cell count, and stomatitis. Since ritexitinib is a new drug for the treatment of alopecia areata, it has not yet been marketed in China and has not been included in medical insurance. Its price has not yet been learned. For specific prices and drug details, you can consult a medical consultant.